clinical trials

Faeth Therapeutics is a clinical-stage oncology company pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway. Its lead candidate PIKTOR is an all-oral combination designed to inhibit PI3K-alpha, mTORC1, and mTORC2 simultaneously. The company was founded in 2019 and in February 2026 was acquired by Sensei Biotherapeutics, making PIKTOR the combined company's lead program.

drug developmentpreclinical research

FamilyTrac, Inc. provides FamilyTrac, a cloud-hosted Software as a Service (SaaS) platform serving public health and social programs. It supports family services case management and reporting, newborn hearing and bloodspot screening, early intervention, maternal and child health, study management systems and clinical trials, and vital records including electronic birth, death, and fetal death registration. The company is registered in North Carolina and is majority women owned.

case management and reporting data systemconfigurable tracking solutionselectronic birth registrationelectronic case reportingelectronic death registrationelectronic fetal death registrationelectronic lab reportingstudy management systemssyndromic surveillance

Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system. Its lead asset bexmarilimab is a first-in-class anti-Clever-1 antibody being investigated in Phase I/II clinical trials for hematological cancers and solid tumors.

drug developmentimmunotherapy researchpreclinical development

FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. Its M2SR Vaccine Platform is a clinically-tested vaccine candidate addressing unmet needs in flu prevention, including consistent efficacy, annual virus drift, and shedding. The flagship candidate M2SR is an intranasal, supra-seasonal flu vaccine that stimulates mucosal, humoral, and cellular immunity. Long-term R&D plans include potential application against SARS-CoV-2 (COVID-19) and other respiratory diseases such as RSV.

intranasal vaccinepre-clinical researchvaccine development

Gaia Medical Institute, Inc. is a La Jolla, California-based diagnostics company developing BrainGuardian™, a rapid, non-invasive saliva test for concussion detection. The test uses patented technology targeting TBI biomarkers in saliva cells, with a reported 94% accuracy and results in under 15 minutes. The company reports 9 issued patents, over $15.8 million in non-dilutive government funding, and clinical testing of 1,059 subjects across 3 NIH studies. It operates a BSL-2 laboratory in the La Jolla Biotech Hub.

BSL-2 laboratoryresearch and developmentsaliva-based diagnostic testingTBI biomarker detection in saliva cells

Gameto is a biotechnology company focused on women's reproductive health, developing cell engineering solutions for infertility, IVF, egg freezing, and menopause. Its lead product, Fertilo, uses engineered ovarian support cells to enable egg maturation outside the body, aiming to make IVF and egg freezing shorter and easier. Fertilo is an investigational biologic in a U.S. Phase 3 clinical trial and is not FDA-approved for marketing in the US.

cell engineeringembryologyin vitro maturationiPSC-derived technologystem cell biology

Gamma Biotherapeutics is a private, clinical-stage biotechnology company discovering and developing therapeutics that help the immune system fight cancer. Its lead program M3T01, a FasL-neutralizing monoclonal antibody, is advancing through a Phase 1 first-in-human clinical trial in patients with advanced solid tumors at Providence Cancer Institute in Portland, Oregon.

clinical developmentdrug discoverymonoclonal antibody development

GangaGen Biotechnologies Private Limited (GBPL), India, is a biologics company specialized in discovering, designing and developing novel therapies for treating serious bacterial infections. Its mission is to transform the global fight against anti-microbial resistance by pioneering discovery and development of novel therapies. GBPL was founded and registered in India in 2000 by Prof J. Ramachandran and became a subsidiary of GangaGen Inc., a Delaware company in the US, in 2001. It advanced a candidate compound into human clinical trials for decolonizati

designing novel protein antibacterialsdiscovery and development of biologics

GearJump Technologies is an R&D company that develops platform technologies in engineering and life sciences, with emphasis on controlled drug delivery for medical, agricultural and vector control applications. It combines expertise in nanotechnologies, materials, microsystems, clinical medicine, molecular biology, fluid mechanics, engineering manufacturing, product engineering and regulatory processes. Its mission is to create novel diagnostic and controlled drug delivery platforms addressing problems affecting humans, animals and plants.

bionanotechnologycontrolled drug deliveryelectronicsengineering manufacturingMEMS technologyProduct EngineeringR&Dregulatory processes

General Neuro, Inc. is a public benefit corporation based in Boston, MA, founded at Yale by computational neuroscientist Alec Sheffield along with engineers Luke Knoble and Zida Sung. It builds brain-stimulation headbands, including NeuroLingo, a reading-practice aid for children with dyslexia ages 6 and up that uses transcranial direct current stimulation (tDCS) during reading practice.

brain stimulation headband designcustom head sizingelectrode positioning systemstimulation circuitry engineering

Gibson Oncology is a brain cancer drug development company in Miami, FL focused on glioblastoma therapies. It has begun a Phase II trial of LMP744 in glioblastoma, conducted by the NIH, in 40 patients who failed initial drug. LMP744 has c-Myc and Topo 1 activity, crosses the blood-brain barrier, has strong PDX data in GBM, and has FDA Orphan Drug Status. The FDA says the trial may qualify as a registration trial.

drug development

Gilead Sciences is a biopharma company that discovers, develops and delivers innovative therapeutics for people with life-threatening diseases. Its work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation. The company offers 25+ medicines globally and has 53 clinical programs across virology, oncology and inflammation, and is the #1 funder of philanthropic HIV programs in the U.S.

pharmaceutical development and manufacturingresearch and development

Global Continence Inc. is a medical device company focused on advancing pediatric continence care. It is developing Soluu™, an investigational wearable device using gentle, non-invasive neuromodulation to help children with bedwetting (nocturnal enuresis) recognize bladder fullness and improve nighttime dryness. The company also offers The Ultimate Bedwetting Survival Guide, a resource for parents, and published a survey on practices and challenges in managing bedwetting. The AUA selected Global Continence Inc. as one of the most exciting startups in uro

medical device research and developmentNeuromodulation

Global Neurosciences Institute is a team of neurosurgeons, neurologists and researchers providing comprehensive neurosciences care across New Jersey, Pennsylvania and Delaware. It partners with AtlantiCare and offers patient resources including second opinions, support groups, clinical trials and fellowship programs.

Advanced Stroke Life Support trainingfellowship programsneurologyneurosurgerystroke thrombolysis

Herantis Pharma Plc is a clinical-stage biotechnology company developing neurorestorative therapies aimed at slowing or stopping the progression of Parkinson's disease. Its lead product HER-096 is a CDNF-derived peptidomimetic targeting multiple Parkinson's disease mechanisms. The company is listed on Nasdaq First North Growth Market Finland under the ticker HRTIS.

biomarker researchdrug development

The Nerve and Muscle Center of Texas provides comprehensive clinical, neurophysiological, and pathological evaluation along with therapeutic intervention, teaching, and research in a single location in Houston. Led by Medical Director Aziz Shaibani, MD, the center specializes in evaluation and management of disorders of the peripheral nervous system such as neuropathy, myopathy, and myasthenia gravis.

Autonomic nervous system testingBotulinum toxin injectionsElectromyography (EMG)genetic counselingIV infusionsLumbar punctureMuscle biopsyNerve biopsyNeuromuscular clinicplasmapheresisSkin biopsyTeaching and training

ICON is a clinical research organisation providing outsourced clinical development and commercialisation services to the pharmaceutical, biotechnology and medical device industries. It offers clinical, consulting and commercial services across sectors including biotech, government and public health, medical devices and pharmaceuticals, and has contributed to over 60 FDA/EMA approved therapies in oncology CGT in the last 5 years.

analytical method development and validationclinical developmentformulation developmentglobal depot and distributionmedical imagingpackaging and labellingRegulatory Affairssmall-batch manufacturingstability testingtranslation and linguistic validation

IGC Pharma is a clinical-stage biotechnology/pharmaceutical company focused on Alzheimer's disease and related dementias. Its lead candidate IGC-AD1, a partial CB1 receptor agonist with anti-inflammatory action, targets agitation in Alzheimer's dementia and has completed enrollment in the Phase 2 CALMA trial. The company also develops AI-driven predictive tools such as MINT-AD and PRISM for early Alzheimer's risk prediction and clinical decision support.

artificial intelligence predictive modelingclinical stage drug developmentmanufacturing and processingR&D

IgGenix, Inc. is a clinical-stage antibody discovery and development company with a mission to solve allergies and other immunological diseases. Using its SEQ SIFTER™ single cell RNA-sequencing-based discovery platform, it captures rare human B cells that produce IgE antibodies from human blood and re-engineers fully human, high-affinity, allergen-specific IgG antibodies designed to block the allergic cascade. Its lead candidate IGNX001 targets peanut allergy and has completed a Phase 1 clinical trial.

antibody developmentantibody discoveryantibody re-engineeringobservational studiessingle cell RNA-sequencing

Illinois Retina Associates is a retina practice founded in 1975 that diagnoses and treats diseases of the retina, macula, and vitreous for patients in the Chicago Metropolitan Area and beyond. It operates 13 retina center locations across Illinois and Indiana and participates in national and international clinical research studies.

intravitreal injectionsocular oncologyretinal diagnostic testingretinal laser treatmentvitreoretinal surgery

The Indian Council of Medical Research (ICMR), New Delhi, is the apex body in India for the formulation, coordination and promotion of biomedical research. Established in 1911, it is one of the oldest medical research bodies in the world. ICMR comprises 28 institutes, 762 scientists, 163 Viral Research Diagnostic Laboratories, 117 Multidisciplinary Research Units, 35 Model Rural Health Research Units and 26 Field Units.

biomedical researchdisease surveillanceepidemiological studiesTraining and capacity buildingvaccine development research

INmune Bio Inc. is a clinical stage biotechnology company focused on restoring function in the innate immune system to fight disease. Its pipeline consists of first in class therapies designed to maximize benefit without compromising safety, being developed for neurologic disease and certain forms of cancer. Drug candidates INKmune and INB03 may be used to treat cancer, while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease.

clinical stage drug developmentimmunotherapy development

Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Guided by science and collective expertise, it works closely with patients to understand real-world challenges and develop meaningful solutions. Its therapies include ARIKAYCE and BRINSUPRI, and its areas of innovation include gene therapy with targeted delivery, protein deimmunization, RNA end-joining, and synthetic rescue.

commercializationdrug developmentgene therapy with targeted deliveryprotein deimmunizationresearchRNA end-joiningsynthetic rescue

Insulet (NASDAQ: PODD) is a medical device company headquartered in Acton, Massachusetts, that developed Omnipod, a line of tubeless, wearable, Pod-based insulin management systems. Founded in 2000 by a father determined to free his son from multiple daily insulin injections, the company provides continuous insulin delivery through a wearable, tubeless, waterproof insulin pump called a Pod. Insulet products are available in 26 countries.

manufacturingmedical device engineeringproduct designresearch and development